Dianthus Therapeutics
DNTH
75 hedge funds and large institutions have $54.6M invested in Dianthus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 31 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 20
0.25% less ownership
Funds ownership: 5.09% → 4.84% (-0.25%)
19% less funds holding
Funds holding: 93 → 75 (-18)
52% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 31
61% less capital invested
Capital invested by funds: $139M → $54.6M (-$84.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$1.68M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$900K |
| 3 |
Renaissance Technologies
New York
|
+$760K |
| 4 |
Millennium Management
New York
|
+$728K |
| 5 |
RC
RBF Capital
San Francisco,
California
|
+$574K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$4.07M |
| 2 |
BlackRock
New York
|
-$2.07M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.73M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$930K |
| 5 |
State Street
Boston,
Massachusetts
|
-$657K |
DNTH Hedge Fund Activity: Q2 2022 in Review
75 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2022, worth a combined $54.6M — down 61% from $139M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of DNTH and 15 opened new positions — a net loss of 16 holders — while 20 trimmed existing stakes and 20 added.
The largest buyer was Janus Henderson Group, adding an estimated $1.68M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $4.07M.
- 75 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2022, down from 93 in Q1 2022.
- Funds reported $54.6M of Dianthus Therapeutics stock for Q2 2022, down 61% quarter-over-quarter.
- 15 funds opened new Dianthus Therapeutics positions in Q2 2022 and 31 closed out, a net change of -16 holders.
- The largest Dianthus Therapeutics buyer in Q2 2022 was Janus Henderson Group, an estimated $1.68M added.
- The largest Dianthus Therapeutics seller in Q2 2022 was Gilder Gagnon Howe & Co, an estimated $4.07M sold.
Based on aggregated 13F filings for Q2 2022.